Alzheimer's disease (AD) is the most common neurodegenerative disorder. Worldwide
prevalence of the disease is estimated at more than 24 million cases. With aging of …

The current recommended standard of care for the symptomatic treatment of mild to
moderate Alzheimer's disease is cholinesterase inhibitors. In short-and long-term studies …

OBJECTIVE: To provide a review of acetylcholinesterase inhibitors (AChEIs) tested as
therapeutic agents for Alzheimer disease (AD). DATA SOURCES: MEDLINE searches …

Current pharmacological therapy for Alzheimer's disease (AD) includes the cholinesterase
inhibitors (ChEIs) donepezil, rivastigmine, and galantamine and the N-methyl d-aspartate …

Background** This review is awaiting update with a new protocol. The methods used for the
review were acceptable when the review was published but do not meet contemporary …

The 'second-generation'cholinesterase inhibitors (ChEIs), donepezil, galantamine and
rivastigmine, are a class of medications that are currently approved for the treatment of mild …

Background: We investigated the effect of cholinesterase inhibitors on all-cause
discontinuation, efficacy and safety, and the effects of study design-, intervention-, and …

Introduction: To date, pharmacological treatment of Alzheimer's disease (AD) includes
Acetylcholinesterase Inhibitors (AChEIs) for mild-to-moderate AD, and memantine for …

Cholinesterase inhibitors (ChEIs) were introduced in the therapy of Alzheimer Disease (AD)
in the nineteen nineties with great expectations. The hopes and large interest raised by …

Objectives To report on a Numbers Needed to Treat (NNT) analysis of the literature
identified through a systematic review of trials of cholinesterase inhibitors in Alzheimer's …